Among the various tools used to deliver genetic material, Adeno-associated virus (AAV) has emerged as the preferred choice for many US-based researchers due to its low immune profile and impressive safety record. In 2026, the focus has shifted toward refining these vectors to make them more "tissue-specific," ensuring the therapy reaches only the intended organ without affecting the rest of the...
Russian 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Tiếng Việt